Development and implementation of a RT-qPCR extraction-free protocol for the detection of SARS-CoV-2 and impact on the turn-around-time
© 2021 Wiley Periodicals LLC..
The occurrence of the COVID-19 second-wave outbreak in Europe has pushed laboratories performing molecular SARS-CoV-2 tests to increase their throughput and decrease the result rendering time. In this evaluation, we tested for the first time a new, extraction-free, protocol with the Allplex SARS-CoV-2 Assay RT-qPCR kit on a Nimbus platform. Ninety-one samples, of which 71 previously tested positive with RT-qPCR with extraction were immediately analyzed without extraction, using only a dilution and thermal shock protocol. The positive and negative percentage agreements were respectively 97.2% (95% confidence interval [CI]: 0.90-0.99) and 95.0% (95% CI: 0.76-0.99). The two false negatives observed were very weakly positive with the comparison method. Moderate variations in Ct of the targeted genes were observed (median ± 95% CI): E gene, +2.49 ± 0.44; N gene, +0.98 ± 0.54; RdRP/S genes, +2.64 ± 0.48. On the other hand, the number of tests performed within 24 h raised from 86.4% to 97.8%, the turn-around time decreased from 19:18 to 09:03 (p < .0001), and the number of tests that can be performed per day doubled since this technique was introduced routinely in our laboratory.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
---|---|
Enthalten in: |
Journal of medical virology - 93(2021), 4 vom: 22. Apr., Seite 2538-2542 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Blairon, Laurent [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 19.03.2021 Date Revised 19.03.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/jmv.26782 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM319794180 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM319794180 | ||
003 | DE-627 | ||
005 | 20231225172214.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/jmv.26782 |2 doi | |
028 | 5 | 2 | |a pubmed24n1065.xml |
035 | |a (DE-627)NLM319794180 | ||
035 | |a (NLM)33415765 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Blairon, Laurent |e verfasserin |4 aut | |
245 | 1 | 0 | |a Development and implementation of a RT-qPCR extraction-free protocol for the detection of SARS-CoV-2 and impact on the turn-around-time |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 19.03.2021 | ||
500 | |a Date Revised 19.03.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021 Wiley Periodicals LLC. | ||
520 | |a The occurrence of the COVID-19 second-wave outbreak in Europe has pushed laboratories performing molecular SARS-CoV-2 tests to increase their throughput and decrease the result rendering time. In this evaluation, we tested for the first time a new, extraction-free, protocol with the Allplex SARS-CoV-2 Assay RT-qPCR kit on a Nimbus platform. Ninety-one samples, of which 71 previously tested positive with RT-qPCR with extraction were immediately analyzed without extraction, using only a dilution and thermal shock protocol. The positive and negative percentage agreements were respectively 97.2% (95% confidence interval [CI]: 0.90-0.99) and 95.0% (95% CI: 0.76-0.99). The two false negatives observed were very weakly positive with the comparison method. Moderate variations in Ct of the targeted genes were observed (median ± 95% CI): E gene, +2.49 ± 0.44; N gene, +0.98 ± 0.54; RdRP/S genes, +2.64 ± 0.48. On the other hand, the number of tests performed within 24 h raised from 86.4% to 97.8%, the turn-around time decreased from 19:18 to 09:03 (p < .0001), and the number of tests that can be performed per day doubled since this technique was introduced routinely in our laboratory | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a RT-qPCR | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a extraction free | |
650 | 7 | |a Coronavirus Envelope Proteins |2 NLM | |
650 | 7 | |a Coronavirus Nucleocapsid Proteins |2 NLM | |
650 | 7 | |a Phosphoproteins |2 NLM | |
650 | 7 | |a RNA, Viral |2 NLM | |
650 | 7 | |a envelope protein, SARS-CoV-2 |2 NLM | |
650 | 7 | |a nucleocapsid phosphoprotein, SARS-CoV-2 |2 NLM | |
700 | 1 | |a Piteüs, Sébastien |e verfasserin |4 aut | |
700 | 1 | |a Beukinga, Ingrid |e verfasserin |4 aut | |
700 | 1 | |a Tré-Hardy, Marie |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 93(2021), 4 vom: 22. Apr., Seite 2538-2542 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
773 | 1 | 8 | |g volume:93 |g year:2021 |g number:4 |g day:22 |g month:04 |g pages:2538-2542 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.26782 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 93 |j 2021 |e 4 |b 22 |c 04 |h 2538-2542 |